Objective
to determine whether low dose intracoronary fibrinolysis reduces microvascular dysfunction after primary PCI
Study
placebo-controlled, multicentre, randomised controlled trial
Population
patients with STEMI <6 hours from onset + occlusion of a major coronary artery
Endpoints
microvascular obstruction (MVO) as % of LV mass at MRI at 2-7 days
Conclusion
intracoronary alteplase does not reduce microvascular obstruction in patients undergoing primary PCI
McCartney et al. JAMA. 2019;321:56-68
